Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Staar Surgical ( (STAA) ) has provided an update.
STAAR Surgical reported its financial results for the fourth quarter and fiscal year 2024, highlighting a decline in net sales due to weak macroeconomic conditions in China, the largest market for refractive procedures. The company’s overall performance was affected, with a net loss reported for the year. Despite this, STAAR experienced growth in ICL sales outside of China, with a 17% increase in the fourth quarter of 2024 and a 13% increase for the entire fiscal year. Looking forward, the company anticipates continued growth in global markets excluding China, while managing elevated inventory levels and planning for a potential market rebound in China during the second half of 2025.
More about Staar Surgical
STAAR Surgical Company is a global leader in the ophthalmic industry, specializing in the production of phakic intraocular lenses with its EVO family of Implantable Collamer Lenses (ICLs) for vision correction. The company is focused on advancing visual freedom for patients and maintaining its market leadership in myopia correction with over 30 years of proven clinical outcomes.
YTD Price Performance: -6.18%
Average Trading Volume: 604,243
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.08B
Learn more about STAA stock on TipRanks’ Stock Analysis page.